NuWays keeps Nexstim at Buy, price target EUR 12

Bitget2026/10/09 07:00

NuWays kept its BUY rating on Nexstim, holding a 12-month target price of EUR 12. Analysts flagged Brainlab’s workflow integration as a key catalyst to scale NBS system adoption in diagnostics despite a roughly $300,000 system cost. Therapy recurring revenue fell 14.8% to EUR 1.1 million in H1 2026 as customers shifted to reusable trackers, with gross profit impact seen as limited. Year-to-date announced orders reached 38 systems, covering 83% of NuWays’ FY26 delivery estimate of 46 systems. NuWays left forecasts unchanged, citing seasonality and a Q4 delivery test under the new Brainlab distribution model. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief via EQS News (Ref. ID: rc_27046) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37